DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations

Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Insulin Resistance; Diabetes Mellitus; Abnormal Glucose Metabolism

Intervention: Liothyronine (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Official(s) and/or principal investigator(s):
Rebecca J Brown, M.D., Principal Investigator, Affiliation: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Overall contact:
Rebecca J Brown, M.D., Phone: (301) 594-0609, Email: brownrebecca@mail.nih.gov

Summary

Background:

- Insulin receptor mutation causes high blood sugars and sometimes diabetes complications.

Researchers want to see if thyroid hormone helps. Objectives:

- To see if thyroid hormone treatment changes how the body handles sugar in people with

insulin receptor mutation and improves blood sugar in people with diabetes. Eligibility:

- People ages 12 65 with an insulin receptor mutation.

Design:

- Study part 1: 19-day clinic stay. Participants will be monitored for 4 days. Then for 15

days they will take a thyroid hormone pill 3 times a day. Participants will have:

- Blood tests.

- Heart rate and skin temperature monitored.

- All their food provided.

- Two 5-hour sessions in a special room. They will wear special clothes and sometimes sit

still.

- Two small tubes inserted in veins. One will deliver tiny amounts of sugar and fat with

a non-radioactive tracer. Participants will also drink water with a tracer. The other tube will collect blood.

- A sweet drink. Participants may have finger stick blood sugar tests.

- Glucose-monitoring device inserted into body fat for two 24-hour periods.

- Adults may have samples of fat and muscle taken.

- Heart ultrasound.

- PET-CT scan in a machine. An intravenous catheter will be placed in an arm vein. A

small amount of radioactive substance will be injected.

- DEXA scan of body fat and bone density.

- Participants with poorly controlled diabetes will then take thyroid hormone at home for

6 months. They will have blood drawn and sent to the study team monthly.

- After about 3 months, they will have an overnight visit. After 6 months, they will have

a 4-day visit.

Clinical Details

Official title: Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in Patients With Insulin Receptor Mutations

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Thyroid hormone effects on glucose disposal

Thyroid hormone effects on hemoglobin A1C

Secondary outcome:

Quantification of fractional gluconeogenesis and glycogenolysis using isotopic tracers

Thyroid hormone effects on glucose area under the curve using 7 point daily plasma glucose measurement, continuous interstitial fluid glucose monitoring, and oral glucose tolerance testing

Thyroid hormone effects on tissue-specific glucose disposal in the fasting state in brown adipose tissue, white adipose tissue, and muscle using PET/CT

Detailed description: Background Patients with mutations of the insulin receptor have extreme insulin resistance. This frequently results in diabetes in childhood that is extremely difficult to manage with conventional diabetes therapies, including insulin at doses 10-50 fold higher than usual. Poorly controlled diabetes, in tum, leads to microvascular complications (e. g. blindness) and early death. Hyperthyroidism, whether endogenous (e. g. Graves' disease) or exogenous, increases energy expenditure, activates brown adipose tissue, and enhances skeletal muscle perfusion, leading to enhanced glucose disposal. In a single patient with mutation of the insulin receptor and poorly controlled diabetes despite maximal therapy, iatrogenic mild hyperthyroidism for treatment of thyroid cancer resulted in normalization of glycemia control, suggesting that thyroid hormone treatment could have therapeutic benefit in this rare disease. Aim The purpose ofthis study is to determine iftreatment with thyroid hormone will increase glucose disposal in patients with mutations ofthe insulin receptor, and thereby improve glycemia control. The hypotheses to be tested are: 1. Thyroid hormone will increase whole-body glucose disposal in patients with insulin receptor mutations. 2. This increased glucose disposal will be mediated via increased glucose uptake in BAT and muscle. 3. Increases in glucose disposal will result in improved glycemia control. Methods This study is a non-randomized pre-post design, conducted in two sequential parts. Part 1 is a short-term (2 week) proof-of-principle study to test whether thyroid hormone will increase glucose disposal in patients with insulin receptor mutations (with or without diabetes), and the mechanisms by which increased glucose disposal occurs. Part 2 is a longer term (6 month) therapeutic study to test whether thyroid hormone will result in improved glycemia control in diabetic patients with insulin receptor mutations.

Eligibility

Minimum age: 12 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

- 2 WEEKS STUDY:

INCLUSION CRITRIA: 1. Mutation of the insulin receptor (either recessive or dominant negative). If mutation status is not known prior to enrollment, subjects will undergo genotyping at enrollment. In the unanticipated event that a patient does not have a mutation of the insulin receptor, he or she will not complete the study and his or her data will not be included in the analysis. EXCLUSION CRITERIA: 1. Changes in doses of diabetes medications (including metformin, insulin, sulfonylureas, thiazolidinediones, leptin, GLP-1 agonists, DPP4 inhibitors, etc.) in the preceding 10 weeks. 2. Any medical condition or medication that will increase risk to the subject (e. g. ischemic or structural heart disease, congestive heart failure, uncontrolled hypertension, or arrhythmia) or that will interfere with interpretation of study data. 3. Disorders that would lead to erratic gastrointestinal absorption or loss of thyroid hormone from the gut (severe diarrhea, celiac disease, use of bile acid sequestrants, excessive consumption of soybean products). 4. Any form of endogenous hyperthyroidism or hypothyroidism at baseline. 5. Current or recent (past 8 weeks) use of thyroid hormone or anti-thyroid drugs. 6. Extreme disorders of thyroid hormone binding to thyroid binding globulin (excess or deficiency) or protein loss (nephrotic range proteinuria) that would lead to difficulties achieving a consistent thyroid hormone level for study. 7. Known presence of a rare clinical disorder that leads to thyroid hormone insensitivity (known T3 receptor mutations, selenocysteine insertion sequence-binding protein 2 (SBP2) abnormalities, monocarboxylate transporter defects). 8. Current use of beta blockers 9. Pregnancy or breast feeding 10. Any EKG abnormality that could increase risk of T3 treatment (resting sinus tachycardia (age adjusted norms), atrial fibrillation, myocardial ischemia, left or right ventricular excitation block, left ventricular hypertrophy or extrasystoles) 11. Known allergy or hypersensitivity to any form of thyroid hormone 12. Known adrenal insufficiency 13. Dependence on oral anticoagulant medications (adults only) 14. Use of tricyclic anti-depressants, as transient cardiac arrhythmias have been observed with the concomitant use of thyroid hormone. 15. Use of cholestyramine. 16. History of clinically significant osteoporosis per investigator judgment (e. g. previous fragility fracture) 6 MONTHS STUDY: Patients must meet all inclusion and exclusion criteria for the short-term study, plus have poorly controlled diabetes, defined as a hemoglobin A1c greater than or equal to 7%.

Locations and Contacts

Rebecca J Brown, M.D., Phone: (301) 594-0609, Email: brownrebecca@mail.nih.gov

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States; Recruiting
For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL), Phone: 800-411-1222, Ext: TTY8664111010, Email: prpl@mail.cc.nih.gov
Additional Information

NIH Clinical Center Detailed Web Page

Related publications:

Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976 Apr 1;294(14):739-45.

Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R, Hugendubler L, Cochran C, Solomon J, Chen C, Gorden P. Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insulin resistance. J Clin Endocrinol Metab. 2010 Jan;95(1):256-62. doi: 10.1210/jc.2009-0543. Epub 2009 Nov 6.

Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004 Jul;83(4):209-22. Review.

Starting date: April 2015
Last updated: May 28, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017